Bartlett, TN, November 15, 2008 --(PR.com
)-- InnoPad™ is an injectable implant that is indicated for augmentation of the subdermal fat pad tissue of the plantar surface (bottom) of the foot. Every year, deterioration of the fat pad contributes to the onset of foot ulcers in approximately 20 million diabetic patients worldwide, and serious infections of those ulcers lead to approximately one million lower leg amputations. Foot ulcers and their resulting complications are one of the most significant health issues facing the diabetic community today. InnoPad™ brings to market the work of the late Sol W. Balkin, DPM, who dedicated more than forty years of his career to providing this innovative solution to patients showing signs of fat pad deterioration.
InnoPad™ is Extremity Innovations’ first product to gain regulatory clearances and will help establish the two-year-old company as a leader in providing simple, safe, innovative and economical solutions to the soft tissue field. InnoPad™ is not yet approved by the Food and Drug Administration for commercial distribution in the United States.
About Extremity Innovations, Inc.:
Extremity Innovations, Inc. was founded in April 2006 with a mission to design, develop and market medical devices to address unmet needs and advance the state of the art in the extremities market segment. The company’s first product, InnoPad™, addresses the devastating and debilitating problem of foot ulcers in diabetic patients and will be introduced to the international market in 2008. Based in Bartlett, Tennessee, Extremity Innovations, Inc. is an ISO 13485:2003 registered manufacturer of medical devices.